articleNew England Journal of MedicineOct 24, 2007BRONZE OA

Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer

Dana-Farber Cancer Institute · Sanofi (United States) · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

A randomized phase 3 trial of the treatment of squamous-cell carcinoma of the head and neck compared induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) with cisplatin and fluorouracil (PF), followed by chemoradiotherapy.

Methods

We randomly assigned 501 patients (all of whom had stage III or IV disease with no distant metastases and tumors considered to be unresectable or were candidates for organ preservation) to receive either TPF or PF induction chemotherapy, followed by chemoradiotherapy with weekly carboplatin therapy and radiotherapy for 5 days per week. The primary end point was overall survival.

Citation impact

1,703
total citations
FWCI
84.68
Percentile
100%
References
32
Citations per year

Authors

29

Topics & keywords

Keywords
  • Medicine
  • Docetaxel
  • Carboplatin
  • Fluorouracil
  • Neutropenia
  • Chemoradiotherapy
  • Induction chemotherapy
  • Chemotherapy
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.